ATE522814T1 - Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii - Google Patents
Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin iiInfo
- Publication number
- ATE522814T1 ATE522814T1 AT07846321T AT07846321T ATE522814T1 AT E522814 T1 ATE522814 T1 AT E522814T1 AT 07846321 T AT07846321 T AT 07846321T AT 07846321 T AT07846321 T AT 07846321T AT E522814 T1 ATE522814 T1 AT E522814T1
- Authority
- AT
- Austria
- Prior art keywords
- infections
- provasopressin
- lung
- chronic diseases
- neurophysin
- Prior art date
Links
- 208000017667 Chronic Disease Diseases 0.000 title abstract 2
- 101800000115 Copeptin Proteins 0.000 title abstract 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 102000002710 Neurophysins Human genes 0.000 title 1
- 108010018674 Neurophysins Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 210000004072 lung Anatomy 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 238000013517 stratification Methods 0.000 title 1
- 208000032376 Lung infection Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010064409 proAVP hormone Proteins 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006053442A DE102006053442A1 (de) | 2006-11-12 | 2006-11-12 | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
| PCT/DE2007/002037 WO2008058517A2 (de) | 2006-11-12 | 2007-11-11 | Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE522814T1 true ATE522814T1 (de) | 2011-09-15 |
Family
ID=39277664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07846321T ATE522814T1 (de) | 2006-11-12 | 2007-11-11 | Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8158368B2 (https=) |
| EP (2) | EP2378290B1 (https=) |
| JP (3) | JP5340160B2 (https=) |
| CN (2) | CN101563613A (https=) |
| AT (1) | ATE522814T1 (https=) |
| DE (1) | DE102006053442A1 (https=) |
| DK (1) | DK2378290T3 (https=) |
| ES (2) | ES2370071T3 (https=) |
| HK (1) | HK1215731A1 (https=) |
| WO (1) | WO2008058517A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| PL2084543T3 (pl) | 2006-10-26 | 2018-04-30 | B.R.A.H.M.S Gmbh | Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II |
| DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
| US20120329666A1 (en) * | 2009-10-05 | 2012-12-27 | Duke University | Peripheral Blood Biomarkers for Idiopathic Interstitial Pneumonia and Methods of Use |
| EP2776064A4 (en) | 2011-11-11 | 2015-08-05 | Woomera Therapeutics | PROVASOPRESSINE ANTAGONISTS AND ITS USES |
| EP2637023A1 (en) * | 2012-03-08 | 2013-09-11 | B.R.A.H.M.S GmbH | Prediction of outcome in patients with chronic obstructive pulmonary disease |
| KR102511128B1 (ko) | 2022-03-31 | 2023-03-16 | (주)네오닉스 | 배터리팩 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
| DE10027954A1 (de) | 1999-12-22 | 2001-06-28 | Dade Behring Marburg Gmbh | Humanes Procalcitonin, dessen Herstellung und Verwendung |
| DE50014159D1 (de) | 1999-12-22 | 2007-04-26 | Dade Behring Marburg Gmbh | Lösungen von humanem Procalcitonin |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| ATE491727T1 (de) * | 2002-07-16 | 2011-01-15 | Woomera Therapeutics Inc | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen |
| WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| GB0401730D0 (en) * | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| DE102004047968A1 (de) * | 2004-10-01 | 2006-04-06 | B.R.A.H.M.S Ag | Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen |
| GB0508863D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Peptide |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| JP4983525B2 (ja) * | 2007-10-11 | 2012-07-25 | 住友電装株式会社 | ワイヤハーネスのプロテクタ取付構造 |
| US9229013B2 (en) * | 2009-05-05 | 2016-01-05 | B.R.A.H.M.S Gmbh | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
-
2006
- 2006-11-12 DE DE102006053442A patent/DE102006053442A1/de not_active Withdrawn
-
2007
- 2007-11-11 CN CNA2007800420148A patent/CN101563613A/zh active Pending
- 2007-11-11 US US12/514,524 patent/US8158368B2/en active Active
- 2007-11-11 WO PCT/DE2007/002037 patent/WO2008058517A2/de not_active Ceased
- 2007-11-11 DK DK11170807.9T patent/DK2378290T3/en active
- 2007-11-11 ES ES07846321T patent/ES2370071T3/es active Active
- 2007-11-11 AT AT07846321T patent/ATE522814T1/de active
- 2007-11-11 ES ES11170807.9T patent/ES2634137T3/es active Active
- 2007-11-11 EP EP11170807.9A patent/EP2378290B1/de active Active
- 2007-11-11 CN CN201510454116.7A patent/CN105092858A/zh active Pending
- 2007-11-11 EP EP07846321A patent/EP2089718B1/de active Active
- 2007-11-11 JP JP2009535559A patent/JP5340160B2/ja active Active
-
2012
- 2012-03-21 US US13/425,928 patent/US20120270245A1/en not_active Abandoned
-
2013
- 2013-01-04 JP JP2013000176A patent/JP2013083664A/ja active Pending
-
2015
- 2015-07-31 JP JP2015151852A patent/JP6170101B2/ja active Active
-
2016
- 2016-03-30 HK HK16103639.3A patent/HK1215731A1/zh unknown
- 2016-06-13 US US15/180,797 patent/US10718783B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2378290B1 (de) | 2017-05-03 |
| EP2089718B1 (de) | 2011-08-31 |
| ES2634137T3 (es) | 2017-09-26 |
| US20100041064A1 (en) | 2010-02-18 |
| DK2378290T3 (en) | 2017-07-31 |
| ES2370071T3 (es) | 2011-12-12 |
| JP6170101B2 (ja) | 2017-07-26 |
| US8158368B2 (en) | 2012-04-17 |
| JP2010509576A (ja) | 2010-03-25 |
| EP2378290A1 (de) | 2011-10-19 |
| EP2089718A2 (de) | 2009-08-19 |
| DE102006053442A1 (de) | 2008-05-15 |
| CN101563613A (zh) | 2009-10-21 |
| WO2008058517A3 (de) | 2008-10-23 |
| WO2008058517A2 (de) | 2008-05-22 |
| JP2013083664A (ja) | 2013-05-09 |
| JP2016026286A (ja) | 2016-02-12 |
| US20120270245A1 (en) | 2012-10-25 |
| US20170059583A1 (en) | 2017-03-02 |
| JP5340160B2 (ja) | 2013-11-13 |
| CN105092858A (zh) | 2015-11-25 |
| US10718783B2 (en) | 2020-07-21 |
| HK1215731A1 (zh) | 2016-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE522814T1 (de) | Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii | |
| BR112013006764A2 (pt) | método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente | |
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| EA201290711A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2010027903A8 (en) | Lung cancer diagnosis | |
| WO2011015602A3 (en) | Lung cancer biomarkers | |
| BR112013023540A2 (pt) | anticorpo, kit e método para a determinação de peptídeos amilóides | |
| WO2008040328A3 (de) | Diagnose von infektionen oder entzündungserkrankungen der atemwege und lunge assoziiert mit herzinsuffizienz | |
| NZ594772A (en) | Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c | |
| Gunawardana et al. | Experimental rhinovirus infection in COPD: implications for antiviral therapies | |
| BR112013031354A2 (pt) | "método de perfilar uma amostra de um indivíduo para febre hemorrágica da dengue, método de identificação de um indivíduo com risco de febre hemorrágica da dengue e kit para a identificação de um indivíduo infectado pelo vírus da dengue" | |
| JP2017504011A5 (https=) | ||
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| BRPI0715714A2 (pt) | Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente | |
| JP2017505897A5 (https=) | ||
| NZ599773A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2010105235A3 (en) | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy | |
| JP2010509576A5 (https=) | ||
| JP2006311860A5 (https=) | ||
| SG165370A1 (en) | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites | |
| Knight et al. | Point-of-care lung ultrasound in the assessment of suspected COVID-19: A retrospective service evaluation with a severity score | |
| JP2012523573A5 (https=) | ||
| BR112014007947A2 (pt) | método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5 | |
| BR112013030646A2 (pt) | uso diagnóstico de pró-somatostatina |